LFB BIOMANUFACTURING

manufactures monoclonal antibodies and recombinant proteins through cell culture

Cell line development

Process development and scale-up

Manufacturing of clinical and commercial batches

LFB BIOMANUFACTURING,

an LFB group company, is a CDMO

EMABling®,

our platform for monoclonal antibodies

Cutting-edge know how

Single use technologies

X 3 our production capacity increase

from 2017

01 Mar 2021 LFB GROUP

EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab

13 Apr 2021 Biomanu-facturing

LFB works for « the France of tomorrow » and unveils a new industrial project in Alès

15 Apr 2020 Biomanu-facturing

LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA'S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19

10 Oct 2019 Biomanu-facturing

Festival of Biologics 2019, 15 - 17 October

All news